Latest Biotech News

Researchers at ETH Zurich described a magnetically guided microrobotic platform that navigates vasculature and cerebrospinal spaces in large‑animal models to deliver localized drug payloads. The...

Researchers unveiled UMBS‑seq (Ultra‑Mild Bisulfite Sequencing), a gentler methylation assay that preserves degraded DNA while delivering accurate methylation calls—addressing long‑standing...

Sensei Therapeutics announced a 65% workforce reduction and termination of three executive roles as it winds down development and explores strategic alternatives; the company retains a minimal...

Merck agreed to acquire Cidara Therapeutics for $9.2 billion in cash, securing rights to CD388, a late‑stage long‑acting antiviral designed to prevent seasonal influenza. The deal values Cidara at...

The U.S. Food and Drug Administration approved ziftomenib (Komzifti), a selective oral menin inhibitor developed by Kura Oncology and Kyowa Kirin, for relapsed or refractory acute myeloid leukemia...

Top FDA officials outlined a new regulatory approach — dubbed the "plausible‑mechanism" or bespoke pathway — to accelerate approvals for individualized gene‑editing and personalized biologics when...

Researchers published comprehensive multi‑omic analyses following a genetically modified pig kidney transplanted into a brain‑dead human recipient and maintained for 61 days. Teams tracked tissue,...

Pfizer completed its acquisition of obesity biotech Metsera for up to $10 billion, securing the company’s fast‑acting amylin analog and long‑acting GLP‑1 assets. The purchase ends a heated contest...

Novartis reported that GanLum, a combination including ganaplacide, met its primary endpoint in a large Phase 3 trial across sub‑Saharan Africa and achieved cure rates that meet or exceed WHO...

London‑based venture firm Medicxi closed a €500 million (about $581 million) Fund V to back asset‑centric biotech startups and opportunistic later‑stage investments. The oversubscribed vehicle...

Teams at ETH Zurich reported a clinically‑oriented microrobotics platform that uses electromagnetic navigation to steer dissolvable, drug‑loaded microrobots through complex vasculature and...

Bristol Myers Squibb and Johnson & Johnson suspended a Phase 3 trial of milvexian, a selective factor XIa inhibitor intended as a next‑generation anticoagulant, after an interim analysis showed...

Eli Lilly struck a licensing and research agreement with ABL Bio worth up to $2.6 billion to develop therapeutics using the Grabody‑B blood‑brain barrier (BBB) penetration platform. ABL will...

The U.S. Food and Drug Administration approved ziftomenib (Komzifti) from Kura Oncology and Kyowa Kirin for relapsed or refractory acute myeloid leukemia (AML) with NPM1 mutation. The decision was...

Pfizer finalized a takeover of obesity biotech Metsera in a deal worth up to $10 billion, ending a contentious bidding battle with Novo Nordisk. The acquisition gives Pfizer access to Metsera’s...

Teams published comprehensive multi‑omic analyses following a gene‑edited pig kidney transplanted into a brain‑dead human decedent and monitored for 61 days. Studies in Nature traced immune...

Novartis reported Phase III data for GanLum (ganaplacide + lumefantrine) showing noninferiority to standard artemisinin‑based therapy and cure rates that meet WHO thresholds. The trial enrolled...

London‑based Medicxi announced the close of its fifth fund, Medicxi V, raising €500 million to invest in asset‑centric biotech companies. The oversubscribed fund continues Medicxi’s strategy of...

Eli Lilly struck a license and research agreement with ABL Bio worth up to $2.6 billion to leverage Grabody‑B, a BBB‑penetrating bispecific platform designed to ferry therapeutics into the central...

Nilo Therapeutics announced a $101 million Series A to develop therapies that modulate neural circuits to restore immune homeostasis. Founded by leaders in neurobiology and immunology, Nilo will...